Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Фаза 4 Завершено NCT05436535

Кратко

This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.

Number of Dupilumab-naïve AD Participants With Mild (EASI ≤ 7) vs. Moderate-to-severe (EASI > 7) AD Severity Between Type 2-high vs. Type 2-low Endotype From Non-lesional Skin Transcriptome.

Day 7 · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen

Все исследования